BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus estimates.

Is now the time to buy BIIB? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment and highlighted that, "Biogen is functioning and firing on all cylinders, and doing very well," as the company pivots its commercial focus toward growth products and away from legacy assets.

Looking ahead, Biogen’s guidance reflects confidence in the ongoing expansion of its late-stage pipeline and anticipated regulatory milestones. Management expects key data readouts and potential approvals for several products, including iClick for Alzheimer’s disease and high-dose SPINRAZA in the United States. Dr. Priya Singhal, Head of Development, emphasized the importance of the next eighteen months, noting, “2026 is an important year that begins a multiyear registrational data flow for over the next several years,” with pivotal trials in lupus, kidney transplant, and neurology set to shape the company’s future trajectory.

Key Insights from Management’s Remarks

Management credited strong growth in newly launched therapies and steady performance in multiple sclerosis, while also noting the impact of portfolio prioritization and collaborations.

• Growth products drive momentum: Biogen’s suite of recently launched medicines—Lekembi, Skyclaris, Xerxuve, and Calcadi—generated over $1 billion in annual revenue, with VUMERITY now included in this category due to its resilience amid generic erosion in the oral MS market.
• Pipeline expansion: The company significantly broadened its late-stage development pipeline, adding ten phase three programs and progressing new assets like the BTK degrader for immunology, with management describing this as a deliberate shift toward higher-value projects.
• Lekembi market leadership: Lekembi maintained over 60% share of the anti-amyloid Alzheimer’s therapy market, driven by persistency rates and the introduction of subcutaneous formulations, which management believes will improve patient and physician convenience.
• Strategic business development: Biogen completed the acquisition of Alcion Therapeutics and entered collaborations with Vanqua and Dara Therapeutics, aiming to enhance its position in neurology and immunology.
• MS franchise resilience and challenges: While the legacy MS business continues to face competitive and biosimilar pressures, Tysabri and VUMERITY sustained market share in the U.S., offsetting some of the expected declines from generic entrants in Europe and biosimilars.

Drivers of Future Performance

Biogen’s outlook centers on late-stage pipeline execution, new product launches, and ongoing investments in growth franchises amid continued pressure on legacy assets.

• Regulatory milestones ahead: Management expects pivotal regulatory decisions for iClick (Alzheimer’s) and high-dose SPINRAZA (spinal muscular atrophy) in the U.S. and other key markets, which could drive accelerated adoption if approved and reimbursed.
• Data readouts to shape growth: Multiple phase three trial results, including those for ladifilumab in systemic lupus erythematosus and fezartamab in kidney transplant rejection, are anticipated over the next eighteen months, with positive outcomes likely to support new launches and market expansion.
• Legacy portfolio headwinds: Revenue guidance reflects ongoing declines in the MS business, particularly from generic erosion and biosimilar competition in Europe, partially offset by growth in new medicines and strategic business development.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) the regulatory outcomes for iClick and high-dose SPINRAZA in the U.S., (2) pivotal phase three trial readouts in lupus and kidney transplant rejection, and (3) execution of selective European launches for products like Xerxuve and Skyclaris. The evolution of reimbursement dynamics, particularly for subcutaneous Alzheimer’s therapies, and continued business development activity will also be critical to monitor.

Biogen currently trades at $200.49, up from $185.36 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.